ImmuCell reports Q4 2022 preliminary sales down 28% YoY; full year down 3.5%

IMMUCELL CORP /DE/

2022-FY EPS reported -$0.32 revenue$18,567,962

Q4 2022 sales $3.91M vs $5.44M in Q4 2021, a decline of 28.2%.
FY2022 sales $18.57M vs $19.24M in FY2021, down 3.5%.
Backlog $2.5M as of Dec 31, 2022, up from $205k at Sep 30, 2022, similar to $2.4M a year ago.
Production equipment delays and Q3 contamination events prolonged backlog and reduced output.
Expects to submit Re-Tain CMC Technical Section to FDA in Q1 2023 with 6-month review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IMMUCELL CORP /DE/ reported for the year ended December 31, 2022 results: revenue $18.57 million.

Period: for the year ended December 31, 2022
Revenue: $18.57 million
Result: preliminary results

Exact text from the filing

(% Decrease) During the Three-Month Periods Ended December 31, $ 3.91 million $ 5.44 million $ (1.53 million) (28.2 )% During the Twelve-Month Periods Ended December 31, $ 18.57 million $ 19.24 million $ (675,000 ) (3.5 )% As of December 31, 2022, there was a backlog of orders equal to approximately $2.5 million, representing an increase from

View on SEC.gov

Browse all earnings releases →

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001213900-23-001673

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.